What Is Retatrutide? The Triple-Receptor Peptide That Has the Research World Buzzing
In Phase 2 clinical trials, researchers observed a 24.2% mean body composition change over 48 weeks — surpassing every single and dual agonist studied to date. Here's why the research community is calling it the most significant metabolic peptide discovery in a generation.
